STANDARD BIOTOOLS INC. 8-K

What Happened Standard BioTools Inc. announced on January 30, 2026 that it closed the previously announced sale of all equity interests in SomaLogic, Sengenics Corporation LLC and Sengenics Corporation Pte Ltd to Illumina, Inc. The transaction transfers the Company’s aptamer-based and functional proteomics business (including KREX, Single SOMAmer, SomaScan services and related assays) to Illumina. The Purchase Agreement was dated June 22, 2025; the closing included an upfront cash payment and potential additional consideration and related commercial agreements.

Key Details

• Closing date: January 30, 2026; Purchase Agreement dated June 22, 2025.
• Cash consideration: $350 million upfront paid at closing, plus up to $75 million in earnouts tied to specified net revenue targets for fiscal 2025 and 2026 (total up to $425M).
• Additional arrangements: royalty agreements (royalties on SOMAmer-based NGS library prep kits and on Single SOMAmers), a license for Single SOMAmer IP to Standard BioTools, and a transition services agreement to support the Business post-closing.
• Retained operations: Standard BioTools is keeping its mass cytometry and microfluidics businesses. As a result of the sale, the company and its subsidiaries are no longer parties to the Collaboration Agreement with Illumina Cambridge and will not receive royalties under that agreement.
• Disclosure notes: The company filed a press release (Exhibit 99.1) and cautioned that reported financial results are unaudited and subject to adjustments; representations in the Purchase Agreement were made for contractual purposes and may not reflect the current factual state.

Why It Matters For investors, the transaction provides immediate cash of $350M and potential additional cash and royalty streams that could improve liquidity and fund remaining businesses or strategic priorities. At the same time, Standard BioTools has divested its aptamer-based proteomics unit, narrowing its product mix to focus on mass cytometry and microfluidics. The loss of the prior Collaboration Agreement revenues with Illumina is explicit in the filing, so future revenue mix and growth drivers will shift away from the sold business. Financial results tied to this change are unaudited and may be adjusted, and pro forma financial information was provided in the filing.